Clinical Outcomes
The Distribution of the EQ-5D-5L Index in Patient Populations
1 October 2016
EQ-5D data are often summarised by an EQ-5D index, whose distribution for its original version, the EQ-5D-3L, often shows two distinct groups in patient populations, arising…
New Methods for Modelling EQ-5D-5L Value Sets: An Application to English Data
1 January 2016
This paper provides details of how the EQ-5D-5L value set was derived, focusing on the methods used to model the stated preference data. Results for different…
Valuing Health-Related Quality of Life: An EQ-5D-5L Value Set for England
1 January 2016
This paper reports the methods and findings from the EQ-5D-5L value set for England study. The value set is derived from the stated preference data of…
An Investigation of the Feasibility and Cultural Appropriateness of Stated Preference Methods to Generate EQ-5D-5L Values in the United Arab Emirates
1 February 2015
No EQ-5D-5L value sets are currently available in the Middle East to inform decision making in the region’s health care systems. This study tests the feasibility…
Do Respondents Completing Abstract, Hypothetical Priority-setting Exercises Agree With the Policy Implications of Their Choices?
1 February 2015
Stated preference studies are increasingly being used to understand people’s views about the relative importance of different criteria for making health care priority setting decisions. Stated…
What Determines the Shape of an EQ-5D Index Distribution?
1 August 2014
The EQ-5D is one of the most used health-related quality of life instruments worldwide. Understanding the characteristics of its underlying data is essential. In this paper,…
Multi-Criteria Decision Analysis to Value Orphan Medicines
1 May 2013
The purpose of this research is to identify the attributes to include in a value framework for orphan medicinal products (OMPs), determine their relative importance using…
Understanding Social Preferences Regarding the Prioritisation of Treatments Addressing Unmet Need and Severity
1 December 2012
The UK Government is proposing to include “burden of illness” criteria in its scheme for value based pricing of branded medicines, potentially according higher rewards to medicines…
Valuing Health at the End of Life: A Stated Preference Discrete Choice Experiment
1 December 2012
In 2009, the UK’s National Institute for Health and Clinical Excellence (NICE) issued supplementary advice that its Appraisal Committees are to consider when assessing treatments that…